GRAY - Graybug Vision completes treatment phase of mid-stage ALTISSIMO trial in wet AMD

Clinical-stage biopharmaceutical company Graybug Vision ([[GRAY]] +0.9%) completes its GB-102 Phase 2b ALTISSIMO core trial ((the 12-month treatment phase)) in wet age-related macular degeneration ((wet AMD)) with top-line data expected in the second quarter of 2021.Of the 56 patients enrolled in ALTISSIMO, 50 patients completed the 12-month treatment phase, while the remaining six patients withdrew for reasons unrelated to their treatment with GB-102.Graybug’s lead product candidate, GB-102, is a proprietary microparticle depot formulation of the pan-vascular endothelial growth factor ((pan-VEGF)) inhibitor, sunitinib malate, designed to be administered intravitreally twice per year.GB-102 seeks to reduce the need for frequent intravitreal injections by expanding treatment duration to six months, and potentially longer.58 percent of patients who completed their month 12 visit were eligible and agreed to continue clinical monitoring in a six-month extension of the trial. Goal of the extension period is to observe further durability of GB-102 in wet AMD patients.Wet AMD is one

For further details see:

Graybug Vision completes treatment phase of mid-stage ALTISSIMO trial in wet AMD